Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on Hard-to-Treat cancers in early trial

NCT ID NCT07231081

Recruiting now Disease control Sponsor: Tcelltech Inc. Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated Apr 28, 2026 · Updated 18 times

Summary

This early-phase study tests a new treatment called TX103 CAR-T cells in 85 adults with advanced solid tumors that have not responded to standard therapy. The therapy uses a patient's own immune cells, modified to target a protein (B7-H3) on cancer cells. The main goals are to check safety, find the best dose, and see if it can shrink tumors or slow disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    NOT_YET_RECRUITING

    Beijing, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Beijing Gaobo Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

SOLID TUMORS SOLID TUMORS